Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RAIL

Financiado

Cerrado

Radiomics of lung cancer RAIL non invasive stratification of tumour heterogen...

Radiomics of lung cancer RAIL non invasive stratification of tumour heterogeneity for personalised cancer therapy Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually. It also places the highest economic burden of all cancers on the EU with EUR 18.8 billion. Non-small cell lung cancer (NSCLC) c... ver más

31/03/2020

PT THERAGNOSTIC

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

PT THERAGNOSTIC BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-31

PHC-12-2014: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

PT THERAGNOSTIC

2.43M€ | Lider

Proyectos interesantes

PDC2022-133865-I00

Medical Technol...

Data Science

127K€ Cerrado

BioMedBC

Medical Technol...

Data Science

159K€ Cerrado

HYPOXIMMUNO

Medical Technol...

Data Science

2M€ Cerrado

PTQ-11-04492

Medical Technol...

Biomedical Imag...

67K€ Cerrado

RTC-2017-6597-1

Medical Technol...

Data Science

136K€ Cerrado

CANOMICS

Medical Technol...

Data Science

86K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 58 meses Fecha Inicio: 2015-05-28
Fecha Fin: 2020-03-31

Líder del proyecto

PT THERAGNOSTIC BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually. It also places the highest economic burden of all cancers on the EU with EUR 18.8 billion. Non-small cell lung cancer (NSCLC) comprises 85% of all lung cancer cases. The current clinical routine to guide treatment for NSCLC patients is primarily based on the TNM staging system founded in 1958, mainly to look at surgical operability. However, TNM-based evaluation, nor doctors prediction do not provide an accurate prognosis. The heterogeneity between patients (inter-patient), tumours (inter-tumour) and even within one tumour (intra-tumour) underlies these highly variable prognosis and presents a major clinical challenge. There is a lack of easy to perform, ‘actionable’ biomarkers to stratify NSCLC patients which results in i) under-treatment in 20% of NSCLC patients leading to disease progression and ultimately death, ii) over-treatment in 30% of NSCLC patients which reduces the quality of life of patients and places an economic burden on the healthcare system and iii) ineffective clinical trial design, due to lack of optimal stratification, which requires very large, costly clinical trials to be performed in order to bring new therapeutic strategies to the market. ptTheragnostic has developed breakthrough technology, called Radiomics, which was recently published in Nature Communications, which enables patient stratification through the use of imaging biomarkers acquired from routine CT & PET imaging (see animation on www.pttheragnostic.com). In Radiomics for lung cancer (RAIL) we will validate and qualify a multi-site level I imaging biomarker together with a ready-to-use application to deliver more accurate prognostic information, personalise treatment for NSCLC patients, reduce healthcare costs by EUR 500+ million and enable efficient clinical trial design.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores